176 related articles for article (PubMed ID: 15075501)
1. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.
Brew BJ
AIDS; 2004 Jan; 18 Suppl 1():S75-8. PubMed ID: 15075501
[TBL] [Abstract][Full Text] [Related]
2. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy.
Saavedra-Lozano J; Ramos JT; Sanz F; Navarro ML; de José MI; Martín-Fontelos P; Mellado MJ; Leal JA; Rodriguez C; Luque I; Madison SJ; Irlbeck D; Lanier ER; Ramilo O
Pediatr Infect Dis J; 2006 Dec; 25(12):1142-52. PubMed ID: 17133160
[TBL] [Abstract][Full Text] [Related]
3. HAART & the molecular biology of AIDS dementia complex.
Saksena NK; Smit TK
Indian J Med Res; 2005 Apr; 121(4):256-69. PubMed ID: 15817943
[TBL] [Abstract][Full Text] [Related]
4. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
Wright EJ
Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
[TBL] [Abstract][Full Text] [Related]
5. AIDS dementia complex in China.
Wu YC; Zhao YB; Tang MG; Zhang-Nunes SX; McArthur JC
J Clin Neurosci; 2007 Jan; 14(1):8-11. PubMed ID: 17070055
[TBL] [Abstract][Full Text] [Related]
6. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy.
Carvalhal AS; Rourke SB; Belmonte-Abreu P; Correa J; Goldani LZ
Infection; 2006 Dec; 34(6):357-60. PubMed ID: 17180595
[No Abstract] [Full Text] [Related]
8. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients.
Cysique LA; Brew BJ; Halman M; Catalan J; Sacktor N; Price RW; Brown S; Atkinson JH; Clifford DB; Simpson D; Torres G; Hall C; Power C; Marder K; McArthur JC; Symonds W; Romero C
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):426-9. PubMed ID: 16010165
[TBL] [Abstract][Full Text] [Related]
9. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
10. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
Valle M; Price RW; Nilsson A; Heyes M; Verotta D
Brain; 2004 May; 127(Pt 5):1047-60. PubMed ID: 15013955
[TBL] [Abstract][Full Text] [Related]
11. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
Cysique LA; Maruff P; Brew BJ
Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
[TBL] [Abstract][Full Text] [Related]
12. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.
Dore GJ; McDonald A; Li Y; Kaldor JM; Brew BJ;
AIDS; 2003 Jul; 17(10):1539-45. PubMed ID: 12824792
[TBL] [Abstract][Full Text] [Related]
13. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
14. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
15. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy.
McCoig C; Castrejón MM; Castaño E; De Suman O; Báez C; Redondo W; McClernon D; Danehower S; Lanier ER; Richardson C; Keller A; Hetherington S; Sáez-Llorens X; Ramilo O
J Pediatr; 2002 Jul; 141(1):36-44. PubMed ID: 12091849
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
[TBL] [Abstract][Full Text] [Related]
17. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.
Chang L; Ernst T; Witt MD; Ames N; Walot I; Jovicich J; DeSilva M; Trivedi N; Speck O; Miller EN
Antivir Ther; 2003 Feb; 8(1):17-26. PubMed ID: 12713060
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
Maggiolo F; Callegaro A; Arici C; Quinzan G; Gregis G; Ripamonti D; Tebaldi A; Goglio A; Suter F
Antivir Ther; 2003 Apr; 8(2):121-6. PubMed ID: 12741624
[TBL] [Abstract][Full Text] [Related]
19. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy.
Sacktor N
J Neurovirol; 2002 Dec; 8 Suppl 2():115-21. PubMed ID: 12491162
[TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
